Disclosure under Regulation 30 of SEBI (LODR), Regulation 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 9.3 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Royal Sense Ltd has received final approval from the U.S. Food and Drug Administration (US FDA) on 15th April 2025. The approval covers three nebulizer product categories: medicinal non-ventilatory nebulizers (including nebulizer kits and masks), electrically powered portable nebulizers, and manual nebulizers. This certification allows the company to manufacture and market these medical devices in the U.S. market. The company had filed an application earlier in compliance with FDA requirements.
This FDA approval opens the door for Royal Sense to sell nebulizer products in the lucrative U.S. healthcare market, potentially boosting future revenues and export earnings. For a small company, this is a positive milestone that could attract investor interest, though actual revenue impact will depend on how quickly the company commercializes these products.